<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MENTAX- butenafine hydrochlorideÂ creamÂ </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_48b0b4e9-1a9e-410e-818a-2662352ebd13"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Mentax<span class="Sup">Â®</span> Cream, 1%, contains the synthetic antifungal agent, butenafine hydrochloride. Butenafine is a member of the class of antifungal compounds known as benzylamines which are structurally related to the allylamines.</p>
<p>Butenafine HCl is designated chemically as N-4-<span class="Italics">tert</span>-butylbenzyl-N-methyl-1-naphthalenemethylamine hydrochloride. The compound has the molecular formula C<span class="Sub">23</span>H<span class="Sub">27</span>Nâ€¢HCl, a molecular weight of 353.93, and the following structural formula:</p>
<div class="Figure">
<a name="id659897174"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=167ecefd-4553-41b8-8160-81a48dbca076&amp;name=1774d845-2b53-4c7b-8b66-74e053517c2e-01.jpg">
</div>
<p>Butenafine HCl is a white, odorless, crystalline powder. It is freely soluble in methanol, ethanol, and chloroform, and slightly soluble in water. Each gram of Mentax<span class="Sup">Â®</span> Cream, 1%,Â contains 10 mg of butenafine HCl in a white cream base of purified water USP, propylene glycol dicaprylate, glycerin USP, cetyl alcohol NF, glyceryl monostearate SE, white petrolatum USP, stearic acid NF, polyoxyethylene (23) cetyl ether, benzyl alcohol NF, diethanolamine NF, and sodium benzoate NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_cdcd49a1-b601-4624-bf62-0db6f6021b7e"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_9c4fdc70-08a3-442f-a594-96689773c2bf"></a><a name="section-2.1"></a><p></p>
<h2><span class="Underline">Pharmacokinetics</span></h2>
<p class="First">In one study conducted in healthy subjects for 14 days, 6 grams of Mentax<span class="Sup">Â®</span> Cream, 1%, was applied once daily to the dorsal skin (3,000 cm<span class="Sup">2</span>) of 7 subjects, and 20 grams of the cream was applied once daily to the arms, trunk and groin areas (10,000 cm<span class="Sup">2</span>) of another 12 subjects. After 14 days of topical applications, the 6-gram dose group yielded a mean peak plasma butenafine HCl concentration, Cmax of 1.4 Â± 0.8 ng/mL, occurring at a mean time to the peak plasma concentration, Tmax, of 15 Â± 8 hours, and a mean area under the plasma concentration-time curve, AUC<span class="Sub">0-24 hrs</span> of 23.9 Â± 11.3 ng-hr/mL. For the 20-gram dose group, the mean Cmax was 5.0 Â± 2.0 ng/mL, occurring at a mean Tmax of 6 Â± 6 hours, and the mean AUC<span class="Sub">0-24 hrs</span> was 87.8 Â± 45.3 ng-hr/mL. A biphasic decline of plasma butenafine HCl concentrations was observed with the half-lives estimated to be 35 hours and &gt; 150 hours, respectively.</p>
<p>At 72 hours after the last dose application, the mean plasma concentrations decreased to 0.3 Â± 0.2 ng/mL for the 6-gram dose group and 1.1 Â± 0.9 ng/mL for the 20-gram dose group. Low levels of butenafine HCl remained in the plasma 7 days after the last dose application (mean: 0.1 Â± 0.2 ng/mL for the 6-gram dose group, and 0.7 Â± 0.5 ng/mL for the 20-gram dose group). The total amount (or % dose) of butenafine HCl absorbed through the skin into the systemic circulation has not been quantitated. It was determined that the primary metabolite in urine was formed through hydroxylation at the terminal <span class="Italics">t</span>-butyl side-chain.</p>
<p>In 11 patients with <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, butenafine HCl cream, 1%, was applied by the patients to cover the affected and immediately surrounding skin area once daily for 4 weeks, and a single blood sample was collected between 10 and 20 hours following dosing at 1, 2 and 4 weeks after treatment. The plasma butenafine HCl concentration ranged from undetectable to 0.3 ng/mL.</p>
<p>In 24 patients with <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, butenafine HCl cream, 1%, was applied by the patients to cover the affected and immediately surrounding skin area once daily for 2 weeks (mean average daily dose: 1.3 Â± 0.2 g). A single blood sample was collected between 0.5 and 65 hours after the last dose, and the plasma butenafine HCl concentration ranged from undetectable to 2.52 ng/mL (mean Â± SD: 0.91 Â± 0.15 ng/mL). Four weeks after cessation of treatment, the plasma butenafine HCl concentration ranged from undetectable to 0.28 ng/mL.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_c1863988-096d-43b7-a047-383832c7395c"></a><a name="section-2.2"></a><p></p>
<h2><span class="Underline">Microbiology</span></h2>
<p class="First">Butenafine HCl is a benzylamine derivative with a mode of action similar to that of the allylamine class of antifungal drugs. Butenafine HCl is hypothesized to act by inhibiting the epoxidation of squalene, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. The benzylamine derivatives, like the allylamines, act at an earlier step in the ergosterol biosynthesis pathway than the azole class of antifungal drugs. Depending on the concentration of the drug and the fungal species tested, butenafine HCl may be fungicidal or fungistatic <span class="Italics">in vitro</span>. However, the clinical significance of these <span class="Italics">in vitro</span> data are unknown.</p>
<p>Butenafine HCl has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <a href="#i4i_indications_id_040deef7-4f1c-49a4-bcd7-d5300a5f61e1">INDICATIONS AND USAGE</a> section:</p>
<p><span class="Italics">Epidermophyton floccosum</span><br><span class="Italics">Trichophyton rubrum</span><br><span class="Italics">Malassezia furfur</span><br><span class="Italics">Trichophyton tonsurans</span><br><span class="Italics">Trichophyton mentagrophytes</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_12d702f2-03da-495f-a223-6048fe222ade"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4824c6c8-f781-444c-9f93-5ad6440359b8"></a><a name="section-3.1"></a><p></p>
<h2><span class="Underline"><span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea</span> (pityriasis) versicolor</span></h2>
<p class="First">In the following data presentations, patients with <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor were studied. The term <span class="Bold">â€œNegative Mycologyâ€? </span>is defined as absence of hyphae in a KOH preparation of skin scrapings, i.e., no fungal forms seen or the presence of yeast cells (blastospores) only. The term <span class="Bold">â€œEffective Treatmentâ€? </span>is defined as Negative Mycology plus total signs and symptoms score (on a scale from zero to three) for <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> equal to or less than 1 at Week 8. The term <span class="Bold">â€œComplete Cureâ€? </span>refers to patients who had Negative Mycology plus sign/symptoms score of zero for <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>Two separate studies compared MentaxÂ® Cream to vehicle applied once daily for 2 weeks in the treatment of <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor. Patients were treated for 2 weeks and were evaluated at the following weeks post-treatment: 2 (Week 4) and 6 (Week 8). All subjects with a positive baseline KOH and who were dispensed medications were included in the â€œintent-to-treatâ€? analysis shown in the table below. Statistical significance (Mentax<span class="Sup">Â®</span> vs. vehicle) was achieved for Effective Treatment, but not Complete Cure at 6 weeks post-treatment in Study 31. Marginal statistical significance (p = 0.051) (Mentax<span class="Sup">Â®</span> vs. vehicle) was achieved for Effective Treatment, but not Complete Cure at 6 weeks post-treatment in Study 32. Data from these two controlled studies are presented in the table below.</p>
<a name="_Refid_f126d3f5-17b6-421d-924c-0b07113a8"></a><table width="100%">
<caption><span>Proportion (%) of responders in pivotal clinical trials (all randomized patients)</span></caption>
<col width="17%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="17%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Negative Mycology plus absence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>Negative Mycology plus no or minimal involvement of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling or <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>Absence of hyphae in a KOH preparation of skin scrapings, i.e., no fungal forms seen or the presence of yeast cells (blastospores) only.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First">Patient Response<br>Category</p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"><p class="First">Week @</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First">Study 31</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First">Study 32</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Butenafine</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Vehicle</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Butenafine</p></td>
<td class="Botrule Rrule" align="center"><p class="First">Vehicle</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Complete Cure<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">41/87 (47%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11/40 (28%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">29/85 (34%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">12/41 (29%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">43/86 (50%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15/42 (36%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">36/83 (43%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13/41 (32%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">44/87 (51%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15/42 (36%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">30/86 (35%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10/43 (23%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Effective Treatment<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">56/87 (64%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">16/40 (40%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">46/85 (54%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">16/41 (39%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">50/86 (58%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">19/42 (45%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">45/83 (54%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">16/41 (39%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">48/87 (55%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15/42 (36%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">37/86 (43%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11/43 (26%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Negative Mycology<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a> Â </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">57/87 (66%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">20/40 (50%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">57/85 (67%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">21/41 (51%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">51/86 (59%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">20/42 (48%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">52/83 (63%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">18/41 (44%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">48/87 (55%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15/42 (36%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">43/86 (50%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">12/43 (28%)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="6"><p class="First">@ Week 2 (end of treatment), Week 4 (2 week post-treatment), and Week 8 (6 weeks post-treatment)</p></td></tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea</span> (pityriasis) versicolor is a superficial, chronically recurring <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of the glabrous skin caused by <span class="Italics">Malassezia furfur</span> (formerly <span class="Italics">Pityrosporum orbiculare</span>). The commensal organism is part of the normal skin flora. In susceptible individuals, the condition may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms, and upper thighs.</p>
<p>Treatment of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may not immediately result in restoration of pigment of the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending upon individual skin type and incidental sun exposure. The rate of recurrence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is variable.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_040deef7-4f1c-49a4-bcd7-d5300a5f61e1"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Mentax<span class="Sup">Â®</span> (butenafine HCl) Cream, 1% is indicated for the topical treatment of the dermatologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor due to <span class="Italics">M. furfur </span>(formerly P. orbiculare). Butenafine HCl cream was not studied in immunocompromised patients. (See <a href="#i4i_dosage_admin_id_582a5a68-16da-46de-91b1-260dd49e10de">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_11ad19be-22da-438c-bf8f-494505414c53"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Mentax<span class="Sup">Â®</span> (butenafine HCl) Cream, 1%, is contraindicated in individuals who have known or suspected sensitivity to Mentax<span class="Sup">Â®</span> Cream, 1%, or any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_6ddc14fa-5c51-4ab1-8a86-460df782fd75"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Mentax<span class="Sup">Â®</span> (butenafine HCl) Cream, 1%, is not for ophthalmic, oral, or intravaginal use.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_b70a7b07-f3a6-4270-a91f-1be90aca4dfe"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_2aed7e07-a78c-4635-9325-1d8fa14db9a1"></a><a name="section-7.1"></a><p></p>
<h2><span class="Underline">General</span></h2>
<p class="First">Mentax<span class="Sup">Â®</span> Cream, 1%, is for external use only. If irritation or sensitivity develops with the use of Mentax<span class="Sup">Â®</span> Cream, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by culture on an appropriate medium, [except <span class="Italics">M. furfur </span>(formerly <span class="Italics">P. orbiculare</span>)] or by direct microscopic examination of infected superficial epidermal tissue in a solution of potassium hydroxide.</p>
<p>Patients who are known to be sensitive to allylamine antifungals should use Mentax<span class="Sup">Â® </span>(butenafine HCl) Cream, 1%, with caution since cross-reactivity may occur.</p>
<p>Use Mentax<span class="Sup">Â®</span> Cream, 1%, as directed by the physician, and avoid contact with the eyes, nose, mouth, and other mucous membranes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ae1c400-acd0-4593-957b-c7677cbbfd1e"></a><a name="section-7.2"></a><p></p>
<h2><span class="Underline">Information for Patients</span></h2>
<p class="First">The patient should be instructed to:</p>
<dl>
<dt>1.</dt>
<dd>Use Mentax<span class="Sup">Â®</span> Cream, 1%, as directed by the physician. The hands should be washed after applying the medication to the affected area(s). Avoid contact with the eyes, nose, mouth, and other mucous membranes. Mentax<span class="Sup">Â®</span> Cream, 1%, is for external use only.</dd>
<dt>2.</dt>
<dd>Dry the affected area(s) thoroughly before application, if you wish to apply Mentax<span class="Sup">Â® </span>Cream, 1%, after bathing.</dd>
<dt>3.</dt>
<dd>Use the medication for the full treatment time recommended by the physician, even though symptoms may have improved. Notify the physician if there is no improvement after the end of the prescribed treatment period, or sooner, if the condition worsens (see below).</dd>
<dt>4.</dt>
<dd>Inform the physician if the area of application shows signs of increased irritation, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or oozing.</dd>
<dt>5.</dt>
<dd>Avoid the use of occlusive dressings unless otherwise directed by the physician.</dd>
<dt>6.</dt>
<dd>Do not use this medication for any disorder other than that for which it was prescribed.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1666b9fa-66bd-4246-98cf-bd2e85f93dd5"></a><a name="section-7.3"></a><p></p>
<h2><span class="Underline">Drug Interactions</span></h2>
<p class="First">Potential drug interactions between Mentax<span class="Sup">Â®</span> (butenafine HCl) Cream, 1%, and other drugs have not been systematically evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f170efff-6809-444c-8aa5-54cb026a2509"></a><a name="section-7.4"></a><p></p>
<h2><span class="Underline">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">Long-term studies to evaluate the carcinogenic potential of Mentax<span class="Sup">Â®</span> Cream, 1%, have not been conducted. Two <span class="Italics">in vitro</span> assays (bacterial reverse mutation test and chromosome aberration test in Chinese hamster <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) and one <span class="Italics">in vivo</span> study (rat micronucleus bioassay) revealed no mutagenic or clastogenic potential for butenafine.</p>
<p>In subcutaneous fertility studies conducted in rats at dose levels up to 25 mg/kg/day (0.5 times the maximum recommended dose in humans for <span class="product-label-link" type="condition" conceptid="134870" conceptname="Pityriasis versicolor">tinea versicolor</span> based on body surface area comparisons), butenafine did not produce any adverse effects on male or female fertility.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_53df80cd-61cb-4332-85d3-aa7f3e214b76"></a><a name="section-7.5"></a><p></p>
<h2><span class="Underline">Pregnancy</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a262a66-a113-495c-9a1b-0de99b44caad"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="Bold"><span class="Underline">Teratogenic Effects: Pregnancy Category C</span></span></h3>
<p class="First">Subcutaneous doses of butenafine (dose levels up to 25 mg/kg/day administered during organogenesis) (equivalent to 0.5 times the maximum recommended dose in humans for <span class="product-label-link" type="condition" conceptid="134870" conceptname="Pityriasis versicolor">tinea versicolor</span> based on body surface area comparisons) were not teratogenic in rats. In an oral embryofetal development study in rabbits (dose levels up to 400 mg butenafine HCl/kg/day administered during organogenesis) (equivalent to 16 times the maximum recommended dose in humans for <span class="product-label-link" type="condition" conceptid="134870" conceptname="Pityriasis versicolor">tinea versicolor</span> based on body surface area comparisons), no treatment-related external, visceral, skeletal malformations or variations were observed.</p>
<p>In an oral peri- and post-natal developmental study in rats (dose levels up to 125 mg butenafine HCl/kg/day) (equivalent to 2.5 times the maximum recommended dose in humans for <span class="product-label-link" type="condition" conceptid="134870" conceptname="Pityriasis versicolor">tinea versicolor</span> based on body surface area comparisons), no treatment-related effects on postnatal survival, development of the F1 generation or their subsequent maturation and fertility were observed.</p>
<p>There are, however, no adequate and well-controlled studies that have been conducted with topically applied butenafine in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d9c43f5c-72e3-4059-8a9b-51a06dce476d"></a><a name="section-7.6"></a><p></p>
<h2><span class="Underline">Nursing Mothers</span></h2>
<p class="First">It is not known if butenafine HCl is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised in prescribing Mentax<span class="Sup">Â®</span> Cream, 1%, to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9eb7af2-7ef8-4bff-9c59-40f5eeb28372"></a><a name="section-7.7"></a><p></p>
<h2><span class="Underline">Pediatric Use</span></h2>
<p class="First">Safety and efficacy in pediatric patients below the age of 12 years have not been studied since <span class="product-label-link" type="condition" conceptid="134870" conceptname="Pityriasis versicolor">tinea versicolor</span> is uncommon in patients below the age of 12 years.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_ca6330be-34c9-4659-b1f3-ef0c191395c9"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In controlled clinical trials, 9 (approximately 1%) of 815 patients treated with Mentax<span class="Sup">Â®</span> Cream, 1%, reported adverse events related to the skin. These included burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and worsening of the condition. No patient treated with Mentax<span class="Sup">Â®</span> Cream, 1%, discontinued treatment due to an adverse event. In the vehicle-treated patients, 2 of 718 patients discontinued because of treatment site adverse events, one of which was severe burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> at the site of application.</p>
<p>In uncontrolled clinical trials, the most frequently reported adverse events in patients treated with MentaxÂ® Cream, 1%, were: <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, irritation, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, each occurring in less than 2% of patients.</p>
<p>In provocative testing in over 200 subjects, there was no evidence of allergic-contact sensitization for either cream or vehicle base for Mentax<span class="Sup">Â®</span> Cream, 1%.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_478fa59c-ad95-4cb0-868c-f088cc740b64"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage of butenafine HCl in humans has not been reported to date.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_582a5a68-16da-46de-91b1-260dd49e10de"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor should apply Mentax<span class="Sup">Â®</span> Cream, 1%, once daily for two weeks. Sufficient Mentax<span class="Sup">Â®</span> Cream should be applied to cover affected areas and immediately surrounding skin of patients with <span class="product-label-link" type="condition" conceptid="134870" conceptname="Pityriasis versicolor">tinea versicolor</span>. If a patient shows no clinical improvement after the treatment period, the diagnosis and therapy should be reviewed.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_01de6967-3825-4b0a-88cb-d1fc4e9db4d7"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Mentax<span class="Sup">Â®</span> (butenafine HCl) Cream, 1%, is supplied in tubes in the following sizes:</p>
<p>15-gram tube (NDC 0378-6151-46)</p>
<p>30-gram tube (NDC 0378-6151-49)</p>
<p>STORE BETWEEN 5Â° and 30Â°C (41Â° and 86Â°F).</p>
<p>Keep this and all medications out of the reach of children.</p>
<p>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505 U.S.A.</p>
<p>REVISED NOVEMBER 2013<br>029.7</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_912aa3bb-5ecc-47dd-b85b-f3c375223e76"></a><a name="section-12"></a><p></p>
<h1>Â </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 15 g </span></p>
<p><span class="Bold">NDC 0378-6151-46</span></p>
<p><span class="Bold">MENTAX<span class="Sup">Â®</span></span><br><span class="Bold">(butenafine HCl) Cream 1%</span></p>
<p>For Topical Dermatologic Use Only -<br>Not for Oral, Ophthalmic or Intravaginal Use</p>
<p>Each gram contains 10 mg of butenafine hydrochloride, purified water USP, propylene glycol <br>dicaprylate, glycerin USP, cetyl alcohol NF, glyceryl monostearate SE, white petrolatum USP, stearic acid <br>NF, polyoxyethylene (23) cetyl ether, benzyl alcohol NF, diethanolamine NF and sodium benzoate NF.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying package insert for full prescribing information.</p>
<p><span class="Bold">For external use only.</span></p>
<p><span class="Bold">Keep this and all medications out of the reach of children.</span></p>
<p><span class="Bold">Store between 5Â° and 30Â°C (41Â° and 86Â°F).</span></p>
<p><span class="Bold">See end flap for lot number and expiration date.</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.<br></span>Morgantown, WV 26505 U.S.A.</p>
<p>Mylan.com</p>
<p>559.6</p>
<div class="Figure">
<a name="id-1540197075"></a><img alt="Mentax (butenafine HCl) Cream 1% Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=167ecefd-4553-41b8-8160-81a48dbca076&amp;name=image-01.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MENTAXÂ 		
					</strong><br><span class="contentTableReg">butenafine hydrochloride cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-6151</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BUTENAFINE HYDROCHLORIDE</strong> (BUTENAFINE) </td>
<td class="formItem">BUTENAFINE HYDROCHLORIDE</td>
<td class="formItem">10Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIETHANOLAMINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-6151-46</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15 g in 1 TUBE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-6151-49</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020524</td>
<td class="formItem">12/31/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>522f1787-4c3c-4ca7-9349-a925d0fdb56c</div>
<div>Set id: 167ecefd-4553-41b8-8160-81a48dbca076</div>
<div>Version: 6</div>
<div>Effective Time: 20131107</div>
</div>
</div>Â <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
